Table 1 Patient demographics and baseline clinical characteristics[8]
Parameter | Total TC (n = 243) | Decitabine (n = 242) |
|---|---|---|
Median age, years (range) | 73.0 (64.0–91.0) | 73.0 (64.0–89.0) |
<70 years | 70 (28.8) | 71 (29.3) |
70–74 years | 74 (30.5) | 76 (31.4) |
≥75 years | 99 (40.8) | 95 (39.3) |
Sex, n (%) | ||
Female | 92 (37.9) | 105 (43.4) |
Male | 151 (62.1) | 137 (56.6) |
Median BSA, m2 (range) | 1.80 (1.3–2.7) | 1.82 (1.4–2.6) |
Median time since AML diagnosis, days (range) | 15.0 (0–398.0) | 14.0 (3.0–346.0) |
Type of AML, n (%) | ||
De novo | 157 (64.6) | 155 (64.0) |
Secondary | 84 (34.6) | 87 (36.0) |
Bone marrow blasts, n (%) | ||
<20% | 8 (3.3) | 4 (1.7) |
20%–30% | 58 (24.1) | 65 (27.0) |
>30%–50% | 74 (30.7) | 67 (27.8) |
>50% | 101 (41.9) | 105 (43.7) |
ECOG PS, n (%) | ||
0 or 1 | 178 (73.2) | 182 (75.3) |
2 | 65 (26.7) | 60 (24.8) |
Cytogenetics, n (%) | ||
Intermediate risk | 154 (63.6) | 152 (63.1) |
Poor risk | 87 (36.0) | 87 (36.1) |
Median hemoglobin, g/dL (range) | 9.4 (5.0–12.6) | 9.3 (5.2–15.0) |
Platelets, n | 213 | 225 |
Median, 109/L (range) | 50.00 (6.0–490.0) | 58.00 (6.0–487.0) |
White blood cells, n | 236 | 237 |
Median, 109/L (range) | 3.69 (0.5–80.9) | 3.10 (0.3–127.0) |